Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Cancer cell or component thereof
Reexamination Certificate
2007-07-03
2007-07-03
Kemmeref, Elizabeth (Department: 1646)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Cancer cell or component thereof
C435S354000, C435S355000, C435S366000, C435S372000, C435S375000, C514S012200, C530S350000, C530S816000, C536S023400
Reexamination Certificate
active
10312245
ABSTRACT:
Methods and compositions are provided for the persistent modification of cell membranes with exogenous proteins so as to alter the function of the cell to achieve effects similar to those of gene therapy, without the introduction of exogenous DNA. DNA sequences, the proteins and polypeptides embodying these sequences are disclosed for modulating the immune system. The modulations include down-regulation, up-regulation and apoptosis.
REFERENCES:
patent: 6042826 (1997-11-01), Caligiuri et al.
patent: 5763223 (1998-06-01), Wiley et al.
patent: 5858776 (1999-01-01), Ostrand-Rosenberg et al.
patent: 6004942 (1999-12-01), Firestein et al.
patent: 6071716 (2000-06-01), Freeman et al.
patent: 6130316 (2000-10-01), Freeman et al.
patent: 6149905 (2000-11-01), Ostrand-Rosenberg et al.
patent: 6218510 (2001-04-01), Sharpe et al.
patent: 6294660 (2001-09-01), Sharpe et al.
patent: 6319709 (2001-11-01), Ostrand-Rosenberg et al.
patent: 6608180 (2003-08-01), Sharpe et al.
patent: 6653444 (2003-11-01), Freeman et al.
patent: WO-97/18307 (1997-05-01), None
patent: WO-99/17801 (1999-04-01), None
patent: WO 9917801 (1999-04-01), None
patent: WO-01/52664 (2001-07-01), None
Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, Morris JC. 2004. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. Journal of Clinical Investigation, 113(11): 1515-1525.
Singh NP, Yolcu ES, Taylor DD, Gercel-Taylor C, Metzinger DS, Dreisbach SK, Shirwan H. 2003. A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity. Cancer Research 63, 4067-4073.
Yolcu ES, Askenasy N, Singh NP, Cherradi SE, Shirwan H. 2002. Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity, 17: 795-808.
Brunschwig EB, Levine E, Trefzer U, Tykocinski ML. 1995. Glycosylphosphatidylinositol-modified murine B7-1 and B7-2 retain costimulator function.Journal of Immunology. 155:5498-5505.
Sano T, Pandori MW, Chen X, Smith CL, Cantor CR. Nov. 24, 1995. Recombinant core streptavidins. Journal of Biological Chemistry. 270(47):28204-28209.
Le et al, 1994. Enzyme Microb. Technol. 16: 496-500.
Green et al, 1990. Methods in Enzymology. 184: 51-67.
Pettit et al. 1998. Trends Biotechnol. 16: 343-349.
Pierce Instructions for EZ-LINK Sulfo-NHS-LC-Biotin Instructions, 1998, 4 pages.
Sigma No. B2463 Product Information, Dec. 19, 1996, 2 pages.
Phillips, A., J Pharm Pharmacology 53: 1169-1174, 2001.
Chen, A., et al., “Hierarchical Costimulator Thresholds for Distinct Immune Responses: Application of a Novel Two-Step Fc Fustion Protein Transfer Method,”The Journal of Immunology, 164, (2000), 705-711.
Darling, D., et al., “In Vitro Immune Modulation by Antibodies Coupled to Tumour Cells,”Gene Therapy, 4, (1997), 1350-1360.
Sano, Takeshi , et al., “A streptavidin-metallothionein chimera that allows specific labeling of biological materials with many different heavy metal ions,”Proc. Nat'l. Acad. Sci. USA, vol. 89, (Mar. 1992), 1534-1538.
Yolcu et al., 2002, Cell Membrane Modification for Rapid Display of Proteins as a Novel Means of Immunomodulation: FasL Decorated Cells Prevent Islet Graft Rejection,Immunity, 17:795-808.
Askenasy et al., 2003, Display of Fas Ligand Protein on Cardiac Vasculature as a Novel Means of Regulating Allograft Rejection,Circulation, 107:r41-r47.
Chen et al., “Hierarchical Costimulator Thresholds for Distinct Immune Responses: Application of a Novel Two-Step Fc Fusion Protein Transfer Method,”The Journal of Immunology, 164:705-711 (2000).
Foley & Lardner LLP
Howard Zachary C.
Kemmeref Elizabeth
Unversity of Louisville Research Foundation, Inc.
LandOfFree
Alteration of cell membrane with B7 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alteration of cell membrane with B7, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alteration of cell membrane with B7 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3808604